SEN. KASSEBAUM'S FDA REFORM BILL TIGHTENS REVIEW PERFORMANCE DEADLINE TO MID-1998; THIRD-PARTY PREMARKET REVIEW OPTION OPPOSED BY LABOR CMTE. CHAIR
This article was originally published in The Gray Sheet
Executive Summary
FDA reform legislation (S 1477) introduced Dec. 13 by Senate Labor and Human Resources Committee Chair Nancy Kassebaum (R-Kan.) presents the agency with a stiff deadline for meeting review performance goals in order to avoid default to third-party product reviews. However, it is a challenge Kassebaum seems to believe FDA can meet, given the Kansas Republican's preference for allowing the agency to implement its own changes rather than going to third-party review.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.